UY36714A - Moduladores alostéricos positivos del receptor muscarínico m2 - Google Patents

Moduladores alostéricos positivos del receptor muscarínico m2

Info

Publication number
UY36714A
UY36714A UY0001036714A UY36714A UY36714A UY 36714 A UY36714 A UY 36714A UY 0001036714 A UY0001036714 A UY 0001036714A UY 36714 A UY36714 A UY 36714A UY 36714 A UY36714 A UY 36714A
Authority
UY
Uruguay
Prior art keywords
positive allosteric
allosteric modulators
treat
muscarinic
receiver
Prior art date
Application number
UY0001036714A
Other languages
English (en)
Inventor
Mondritzki Thomas
Dr Henrik Teller
Brechmann Markus
Thomas Müller
Dr Mark Meininghaus
Dr Hanna Tinel
Dr Kalus Münter
Dr Daniela Fliegner
Dr Melissa Boultadakis Arapinis
Dr Alexandros Vakalopoulos
Dr Anne-Sophie Rebstock
Dr Matthias Wittwer
Dr Alexander Straub
Dr Tobias Marquardt
Dr Katrin Nowak-Reppel
Original Assignee
Bayer Pharma Akttiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Akttiengesellschaft filed Critical Bayer Pharma Akttiengesellschaft
Publication of UY36714A publication Critical patent/UY36714A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud se refiere a moduladores alostéricos positivos del receptor de M2 muscarínico, espe-cialmente a 1-arilnaftiridina-3-carboxamidas 7 sustituidas novedosas, a los procesos de preparación de los mismos, al uso de los mismos, por sí solos o en combinaciones para tratar y/o prevenir enfermedades y al uso de las mismos para producir medicamentos para tratar y/o prevenir enfermedades, en particular para tratar y/o prevenir trastornos cardiovasculares y/o trastornos renales.
UY0001036714A 2015-06-09 2016-06-06 Moduladores alostéricos positivos del receptor muscarínico m2 UY36714A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15171127 2015-06-09
EP16156676 2016-02-22

Publications (1)

Publication Number Publication Date
UY36714A true UY36714A (es) 2016-12-30

Family

ID=56101466

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036714A UY36714A (es) 2015-06-09 2016-06-06 Moduladores alostéricos positivos del receptor muscarínico m2

Country Status (27)

Country Link
US (2) US10435403B2 (es)
EP (2) EP3307741B1 (es)
JP (1) JP6908536B2 (es)
KR (1) KR20180016485A (es)
CN (1) CN107949562B (es)
AU (1) AU2016274433B2 (es)
BR (1) BR112017026561A2 (es)
CA (1) CA2988468A1 (es)
CL (1) CL2017003124A1 (es)
CO (1) CO2017012622A2 (es)
CR (1) CR20170566A (es)
CU (1) CU20170158A7 (es)
DO (1) DOP2017000288A (es)
EA (1) EA035465B1 (es)
EC (1) ECSP17081322A (es)
HK (1) HK1254348A1 (es)
IL (2) IL256119A (es)
MX (1) MX370113B (es)
NI (1) NI201700154A (es)
PE (1) PE20180252A1 (es)
PH (1) PH12017502224A1 (es)
SG (1) SG11201710164QA (es)
TN (1) TN2017000498A1 (es)
TW (1) TW201716405A (es)
UY (1) UY36714A (es)
WO (1) WO2016198342A1 (es)
ZA (1) ZA201800125B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135737B (zh) 2015-06-06 2021-11-05 拨云生物医药科技(广州)有限公司 用于治疗翼状胬肉的组合物和方法
BR112018074450A2 (pt) 2016-06-02 2019-03-19 Cloudbreak Therapeutics, Llc composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma
CA3030204A1 (en) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof
JOP20190045A1 (ar) * 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
JOP20190086A1 (ar) * 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
CN110215899B (zh) * 2019-04-01 2022-03-25 重庆科技学院 一种氨基酸功能化的金属有机骨架材料及其制备方法和应用
BR112021026662A2 (pt) * 2019-09-10 2022-04-12 Cloudbreak Therapeutics Llc Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho
CN111057045A (zh) * 2019-12-18 2020-04-24 安徽红杉生物医药科技有限公司 Hcv ns3/4a蛋白酶抑制剂中间体及其合成方法、应用
MX2022010957A (es) * 2020-03-03 2023-01-24 Twentyeight Seven Inc Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn.
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
CN114105881B (zh) 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途
CN113072480B (zh) * 2021-04-13 2022-09-30 常州佳德医药科技有限公司 一种手性(-)-5-氮杂螺[2.4]庚烷-7-醇、制备方法及应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
IT1239283B (it) * 1989-11-08 1993-10-19 Erba Carlo Spa Uso di un agente muscarinico da solo o insieme ad un noto farmaco antiaritmico per la prevenzione e/o il trattamento dell'aritmia ventricolare.
EP0713487B1 (en) 1993-08-13 2000-04-19 Dong Wha Pharmaceutical Industrial Co. Ltd. Novel quinolone carboxylic acid derivatives
US6964966B2 (en) 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
AU2002361493A1 (en) 2001-12-13 2003-06-23 Wockhardt Limited New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
CN1168446C (zh) * 2002-08-26 2004-09-29 夏国瑾 氢溴酸槟榔碱作为制备抗心律失常药物的应用
BRPI0410787A (pt) * 2003-05-21 2006-06-20 Univ Texas inibição da proteìna cinase c-mu (pkd) como um tratamento para hipertrofia cardìaca e insuficiência cardìaca
JP2005012561A (ja) 2003-06-19 2005-01-13 Sony Corp 画像処理装置、画像処理方法および画像投射装置
JP4725047B2 (ja) * 2003-07-24 2011-07-13 アステラス製薬株式会社 キノロン誘導体又はその塩
WO2005009971A1 (ja) * 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
WO2005026145A2 (en) 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
WO2005026165A1 (en) 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
DE10343098A1 (de) * 2003-09-18 2005-04-14 Bayer Healthcare Ag Tetrahydrochinoxaline und ihre Verwendung
WO2005049602A1 (en) 2003-11-18 2005-06-02 Warner-Lambert Company Llc Quinolone antibacterial agents
JP2007513955A (ja) 2003-12-09 2007-05-31 バーテックス　ファーマシューティカルズ　インコーポレイテッド ナフチリジン誘導体およびそれらのムスカリン受容体の調節剤としての使用
US8673964B2 (en) * 2004-05-20 2014-03-18 Diamedica Inc. Use of drug combinations for treating insulin resistance
TW200800983A (en) * 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
AR057555A1 (es) * 2005-10-27 2007-12-05 Merck Frosst Canada Ltd Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
WO2007067489A1 (en) * 2005-12-05 2007-06-14 Merck & Co., Inc. Quinolone m1 receptor positive allosteric modulators
CN101411705B (zh) * 2007-10-17 2011-06-01 北京赛德维康医药研究院 用于防治动脉粥样硬化的药物组合物
WO2010093341A1 (en) 2009-02-10 2010-08-19 Janssen Pharmaceutica N.V. C-7 isoxazolinyl quinolone/naphthyridine derivatives useful as antibacterial agents
AU2010340142B2 (en) 2009-12-17 2014-05-08 Merck Sharp & Dohme Corp. Quinoline amide M1 receptor positive allosteric modulators
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
CN103183676B (zh) * 2013-03-12 2015-04-08 中国医学科学院医药生物技术研究所 一组1-取代-1,8萘啶甲酰胺衍生物及制备和应用
GB201409044D0 (en) 2014-05-21 2014-07-02 Ucl Business Plc New compounds
US20170313665A1 (en) 2014-11-03 2017-11-02 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
JP6549735B2 (ja) 2015-06-09 2019-07-24 アッヴィ・インコーポレイテッド 核内受容体調節剤
PT3312177T (pt) 2015-06-09 2021-05-17 Onconic Therapeutics Inc Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo
CA3030204A1 (en) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.

Also Published As

Publication number Publication date
IL256119A (en) 2018-02-28
AU2016274433A1 (en) 2018-01-04
CU20170158A7 (es) 2018-06-05
DOP2017000288A (es) 2018-01-31
US20190367516A1 (en) 2019-12-05
US10435403B2 (en) 2019-10-08
US20180297994A1 (en) 2018-10-18
CO2017012622A2 (es) 2018-03-28
TN2017000498A1 (en) 2019-04-12
ZA201800125B (en) 2019-07-31
BR112017026561A2 (pt) 2018-08-14
SG11201710164QA (en) 2018-01-30
NI201700154A (es) 2018-10-19
WO2016198342A1 (de) 2016-12-15
PH12017502224A1 (en) 2018-06-04
MX370113B (es) 2019-12-02
JP2018516970A (ja) 2018-06-28
ECSP17081322A (es) 2018-01-31
IL272017A (en) 2020-02-27
EP3692991A1 (de) 2020-08-12
KR20180016485A (ko) 2018-02-14
EA201890002A1 (ru) 2018-04-30
EP3307741B1 (de) 2020-10-28
CN107949562A (zh) 2018-04-20
CN107949562B (zh) 2021-07-23
CA2988468A1 (en) 2016-12-15
AU2016274433B2 (en) 2020-07-16
MX2017016055A (es) 2018-02-21
JP6908536B2 (ja) 2021-07-28
HK1254348A1 (zh) 2019-07-19
EP3307741A1 (de) 2018-04-18
PE20180252A1 (es) 2018-02-02
CL2017003124A1 (es) 2018-06-01
CR20170566A (es) 2018-03-20
EA035465B1 (ru) 2020-06-22
TW201716405A (zh) 2017-05-16

Similar Documents

Publication Publication Date Title
DOP2017000288A (es) Moduladores alostéricos positivos del receptor muscarínico m2.
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
CL2018003597A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos.
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
MX2021003840A (es) Profarmacos de carbidopa y l-dopa y metodos de uso.
MX2018014154A (es) Polinucleotidos moduladores.
MX385332B (es) Moduladores de ror-gamma.
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
EA201691582A1 (ru) Новые фармацевтические препараты
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
ECSP14008556A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
MX2013012053A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
CL2018002335A1 (es) Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
EA201790785A1 (ru) Производные тетрагидроизохинолина
EA201692109A1 (ru) Варианты антител к фактору d и их применение
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
CL2020001123A1 (es) Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren.
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221114